nodes	percent_of_prediction	percent_of_DWPC	metapath
Pomalidomide—CYP1A2—Pentoxifylline—systemic scleroderma	0.108	0.193	CbGbCtD
Pomalidomide—CYP1A2—Leflunomide—systemic scleroderma	0.103	0.184	CbGbCtD
Pomalidomide—ABCB1—Lisinopril—systemic scleroderma	0.0946	0.169	CbGbCtD
Pomalidomide—ABCB1—Captopril—systemic scleroderma	0.0709	0.127	CbGbCtD
Pomalidomide—ABCB1—Mycophenolate mofetil—systemic scleroderma	0.0558	0.0996	CbGbCtD
Pomalidomide—ABCB1—Prednisone—systemic scleroderma	0.0446	0.0796	CbGbCtD
Pomalidomide—CYP3A4—Mycophenolate mofetil—systemic scleroderma	0.0334	0.0597	CbGbCtD
Pomalidomide—CYP3A4—Prednisone—systemic scleroderma	0.0267	0.0477	CbGbCtD
Pomalidomide—ABCB1—Methotrexate—systemic scleroderma	0.0224	0.04	CbGbCtD
Pomalidomide—PTGS2—Fluocinonide—Mometasone—systemic scleroderma	0.00353	0.624	CbGdCrCtD
Pomalidomide—TNF—Cytokines and Inflammatory Response—CSF1—systemic scleroderma	0.00288	0.0328	CbGpPWpGaD
Pomalidomide—TNF—amb2 Integrin signaling—SELP—systemic scleroderma	0.00261	0.0297	CbGpPWpGaD
Pomalidomide—TNF—Canonical NF-kappaB pathway—TNFAIP3—systemic scleroderma	0.00254	0.029	CbGpPWpGaD
Pomalidomide—TNF—Cytokines and Inflammatory Response—IL13—systemic scleroderma	0.00225	0.0256	CbGpPWpGaD
Pomalidomide—TNF—Caspase Cascade in Apoptosis—TOP1—systemic scleroderma	0.00222	0.0254	CbGpPWpGaD
Pomalidomide—TNF—IL27-mediated signaling events—STAT4—systemic scleroderma	0.00217	0.0247	CbGpPWpGaD
Pomalidomide—PTGS2—skeletal joint—systemic scleroderma	0.00215	0.206	CbGeAlD
Pomalidomide—PTGS2—Fluticasone Propionate—Mometasone—systemic scleroderma	0.00213	0.376	CbGdCrCtD
Pomalidomide—TNF—Spinal Cord Injury—AIF1—systemic scleroderma	0.00211	0.024	CbGpPWpGaD
Pomalidomide—TNF—Apoptosis-related network due to altered Notch3 in ovarian cancer—SMAD7—systemic scleroderma	0.0021	0.024	CbGpPWpGaD
Pomalidomide—TNF—amb2 Integrin signaling—ITGAM—systemic scleroderma	0.00208	0.0238	CbGpPWpGaD
Pomalidomide—TNF—TGF-beta Receptor Signaling—SMAD7—systemic scleroderma	0.00207	0.0236	CbGpPWpGaD
Pomalidomide—TNF—HIV-1 Nef: Negative effector of Fas and TNF-alpha—CD247—systemic scleroderma	0.00203	0.0232	CbGpPWpGaD
Pomalidomide—TNF—amb2 Integrin signaling—CTGF—systemic scleroderma	0.00174	0.0198	CbGpPWpGaD
Pomalidomide—TNF—Signaling events mediated by HDAC Class I—SMAD7—systemic scleroderma	0.00168	0.0192	CbGpPWpGaD
Pomalidomide—TNF—IL23-mediated signaling events—STAT4—systemic scleroderma	0.00163	0.0186	CbGpPWpGaD
Pomalidomide—TNF—TNF receptor signaling pathway —TNFAIP3—systemic scleroderma	0.00146	0.0166	CbGpPWpGaD
Pomalidomide—TNF—Cytokines and Inflammatory Response—IL1A—systemic scleroderma	0.00142	0.0161	CbGpPWpGaD
Pomalidomide—TNF—Folate Metabolism—CSF1—systemic scleroderma	0.00141	0.0161	CbGpPWpGaD
Pomalidomide—PTGS2—Spinal Cord Injury—AIF1—systemic scleroderma	0.0013	0.0149	CbGpPWpGaD
Pomalidomide—TNF—Downstream signaling in naïve CD8+ T cells—CD247—systemic scleroderma	0.00117	0.0133	CbGpPWpGaD
Pomalidomide—PTGS2—Quercetin and Nf-kB/ AP-1 Induced Cell Apoptosis—MMP1—systemic scleroderma	0.00112	0.0128	CbGpPWpGaD
Pomalidomide—TNF—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—CTLA4—systemic scleroderma	0.00111	0.0126	CbGpPWpGaD
Pomalidomide—TNF—Matrix Metalloproteinases—MMP1—systemic scleroderma	0.0011	0.0125	CbGpPWpGaD
Pomalidomide—TNF—Spinal Cord Injury—TNFSF13—systemic scleroderma	0.00103	0.0117	CbGpPWpGaD
Pomalidomide—TNF—Downstream signaling in naïve CD8+ T cells—STAT4—systemic scleroderma	0.00103	0.0117	CbGpPWpGaD
Pomalidomide—TNF—Apoptosis—IRF5—systemic scleroderma	0.00101	0.0115	CbGpPWpGaD
Pomalidomide—TNF—FAS pathway and Stress induction of HSP regulation—IL1A—systemic scleroderma	0.000994	0.0113	CbGpPWpGaD
Pomalidomide—CRBN—digestive system—systemic scleroderma	0.000954	0.0914	CbGeAlD
Pomalidomide—TNF—Allograft Rejection—IL13—systemic scleroderma	0.000953	0.0109	CbGpPWpGaD
Pomalidomide—TNF—Spinal Cord Injury—SELP—systemic scleroderma	0.000918	0.0105	CbGpPWpGaD
Pomalidomide—CRBN—tendon—systemic scleroderma	0.000908	0.087	CbGeAlD
Pomalidomide—PTGS2—artery—systemic scleroderma	0.000901	0.0862	CbGeAlD
Pomalidomide—TNF—Cellular roles of Anthrax toxin—IL1B—systemic scleroderma	0.00087	0.00991	CbGpPWpGaD
Pomalidomide—TNF—Toll-like Receptor Signaling Pathway—IRF5—systemic scleroderma	0.000863	0.00983	CbGpPWpGaD
Pomalidomide—TNF—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—CD40LG—systemic scleroderma	0.00086	0.0098	CbGpPWpGaD
Pomalidomide—TNF—Spinal Cord Injury—RHOB—systemic scleroderma	0.000857	0.00977	CbGpPWpGaD
Pomalidomide—TNF—Matrix Metalloproteinases—MMP2—systemic scleroderma	0.000851	0.0097	CbGpPWpGaD
Pomalidomide—TNF—Integrated Pancreatic Cancer Pathway—TOP1—systemic scleroderma	0.000846	0.00964	CbGpPWpGaD
Pomalidomide—TNF—TNF alpha Signaling Pathway—TNFAIP3—systemic scleroderma	0.000839	0.00956	CbGpPWpGaD
Pomalidomide—PTGS2—Calcium signaling in the CD4+ TCR pathway—CD40LG—systemic scleroderma	0.000822	0.00937	CbGpPWpGaD
Pomalidomide—PTGS2—Prostaglandin Synthesis and Regulation—EDN1—systemic scleroderma	0.00081	0.00922	CbGpPWpGaD
Pomalidomide—TNF—amb2 Integrin signaling—MMP2—systemic scleroderma	0.000808	0.00921	CbGpPWpGaD
Pomalidomide—CRBN—lung—systemic scleroderma	0.000797	0.0763	CbGeAlD
Pomalidomide—TNF—Allograft Rejection—CTLA4—systemic scleroderma	0.000767	0.00874	CbGpPWpGaD
Pomalidomide—TNF—IL27-mediated signaling events—IL1B—systemic scleroderma	0.000761	0.00867	CbGpPWpGaD
Pomalidomide—PTGS2—endothelium—systemic scleroderma	0.000761	0.0729	CbGeAlD
Pomalidomide—TNF—IL23-mediated signaling events—CCL2—systemic scleroderma	0.000757	0.00862	CbGpPWpGaD
Pomalidomide—TNF—Cytokines and Inflammatory Response—IL1B—systemic scleroderma	0.000738	0.00841	CbGpPWpGaD
Pomalidomide—PTGS2—blood vessel—systemic scleroderma	0.000702	0.0672	CbGeAlD
Pomalidomide—PTGS2—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—CTLA4—systemic scleroderma	0.000684	0.00779	CbGpPWpGaD
Pomalidomide—TNF—TWEAK Signaling Pathway—CCL2—systemic scleroderma	0.000684	0.00779	CbGpPWpGaD
Pomalidomide—TNF—Regulation of toll-like receptor signaling pathway—IRF5—systemic scleroderma	0.000674	0.00768	CbGpPWpGaD
Pomalidomide—PTGS2—C-MYB transcription factor network—COL1A2—systemic scleroderma	0.000656	0.00748	CbGpPWpGaD
Pomalidomide—TNF—Monoamine Transport—IL1B—systemic scleroderma	0.000644	0.00734	CbGpPWpGaD
Pomalidomide—TNF—Matrix Metalloproteinases—MMP9—systemic scleroderma	0.00064	0.00729	CbGpPWpGaD
Pomalidomide—PTGS2—Spinal Cord Injury—TNFSF13—systemic scleroderma	0.000637	0.00726	CbGpPWpGaD
Pomalidomide—TNF—Allograft Rejection—HLA-DQB1—systemic scleroderma	0.000631	0.00719	CbGpPWpGaD
Pomalidomide—TNF—amb2 Integrin signaling—MMP9—systemic scleroderma	0.000608	0.00692	CbGpPWpGaD
Pomalidomide—TNF—Regulation of toll-like receptor signaling pathway—TNFAIP3—systemic scleroderma	0.000603	0.00687	CbGpPWpGaD
Pomalidomide—TNF—Allograft Rejection—IL1A—systemic scleroderma	0.0006	0.00683	CbGpPWpGaD
Pomalidomide—TNF—Allograft Rejection—CD40LG—systemic scleroderma	0.000596	0.00679	CbGpPWpGaD
Pomalidomide—TNF—IL27-mediated signaling events—TGFB1—systemic scleroderma	0.000591	0.00674	CbGpPWpGaD
Pomalidomide—TNF—RXR and RAR heterodimerization with other nuclear receptor—TGFB1—systemic scleroderma	0.000591	0.00674	CbGpPWpGaD
Pomalidomide—TNF—Vitamin B12 Metabolism—CCL2—systemic scleroderma	0.000585	0.00667	CbGpPWpGaD
Pomalidomide—TNF—MicroRNAs in cardiomyocyte hypertrophy—EDN1—systemic scleroderma	0.000574	0.00654	CbGpPWpGaD
Pomalidomide—TNF—IL23-mediated signaling events—IL1B—systemic scleroderma	0.000574	0.00654	CbGpPWpGaD
Pomalidomide—TNF—Cytokines and Inflammatory Response—TGFB1—systemic scleroderma	0.000574	0.00654	CbGpPWpGaD
Pomalidomide—PTGS2—Spinal Cord Injury—SELP—systemic scleroderma	0.000568	0.00647	CbGpPWpGaD
Pomalidomide—TNF—Angiopoietin receptor Tie2-mediated signaling—MMP2—systemic scleroderma	0.000566	0.00645	CbGpPWpGaD
Pomalidomide—TNF—SIDS Susceptibility Pathways—IL13—systemic scleroderma	0.000553	0.0063	CbGpPWpGaD
Pomalidomide—PTGS2—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—CD40LG—systemic scleroderma	0.000532	0.00606	CbGpPWpGaD
Pomalidomide—PTGS2—Spinal Cord Injury—RHOB—systemic scleroderma	0.00053	0.00604	CbGpPWpGaD
Pomalidomide—TNF—Angiopoietin receptor Tie2-mediated signaling—NOS3—systemic scleroderma	0.00053	0.00604	CbGpPWpGaD
Pomalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—TOP1—systemic scleroderma	0.000523	0.00596	CbGpPWpGaD
Pomalidomide—Dermatitis—Pentoxifylline—systemic scleroderma	0.00051	0.00152	CcSEcCtD
Pomalidomide—Headache—Pentoxifylline—systemic scleroderma	0.000507	0.00151	CcSEcCtD
Pomalidomide—Feeling abnormal—Captopril—systemic scleroderma	0.000505	0.0015	CcSEcCtD
Pomalidomide—Arthralgia—Mycophenolic acid—systemic scleroderma	0.000503	0.0015	CcSEcCtD
Pomalidomide—Infection—Leflunomide—systemic scleroderma	0.000502	0.00149	CcSEcCtD
Pomalidomide—Anxiety—Mycophenolic acid—systemic scleroderma	0.000501	0.00149	CcSEcCtD
Pomalidomide—Asthenia—Mometasone—systemic scleroderma	0.000501	0.00149	CcSEcCtD
Pomalidomide—Unspecified disorder of skin and subcutaneous tissue—Mycophenolic acid—systemic scleroderma	0.0005	0.00149	CcSEcCtD
Pomalidomide—Tremor—Lisinopril—systemic scleroderma	0.000499	0.00148	CcSEcCtD
Pomalidomide—Cardiac disorder—Mycophenolate mofetil—systemic scleroderma	0.000497	0.00148	CcSEcCtD
Pomalidomide—Nervous system disorder—Leflunomide—systemic scleroderma	0.000496	0.00147	CcSEcCtD
Pomalidomide—Thrombocytopenia—Leflunomide—systemic scleroderma	0.000495	0.00147	CcSEcCtD
Pomalidomide—Pruritus—Mometasone—systemic scleroderma	0.000494	0.00147	CcSEcCtD
Pomalidomide—Anaemia—Lisinopril—systemic scleroderma	0.000492	0.00146	CcSEcCtD
Pomalidomide—Skin disorder—Leflunomide—systemic scleroderma	0.000491	0.00146	CcSEcCtD
Pomalidomide—TNF—TWEAK Signaling Pathway—MMP9—systemic scleroderma	0.000489	0.00557	CbGpPWpGaD
Pomalidomide—Hyperhidrosis—Leflunomide—systemic scleroderma	0.000489	0.00145	CcSEcCtD
Pomalidomide—Musculoskeletal discomfort—Azathioprine—systemic scleroderma	0.000488	0.00145	CcSEcCtD
Pomalidomide—Confusional state—Mycophenolic acid—systemic scleroderma	0.000486	0.00145	CcSEcCtD
Pomalidomide—Angiopathy—Mycophenolate mofetil—systemic scleroderma	0.000486	0.00145	CcSEcCtD
Pomalidomide—Body temperature increased—Captopril—systemic scleroderma	0.000485	0.00144	CcSEcCtD
Pomalidomide—Mediastinal disorder—Mycophenolate mofetil—systemic scleroderma	0.000483	0.00144	CcSEcCtD
Pomalidomide—TNF—Aryl Hydrocarbon Receptor Pathway—IL1B—systemic scleroderma	0.000482	0.00549	CbGpPWpGaD
Pomalidomide—Dry skin—Prednisone—systemic scleroderma	0.000481	0.00143	CcSEcCtD
Pomalidomide—Nausea—Pentoxifylline—systemic scleroderma	0.000481	0.00143	CcSEcCtD
Pomalidomide—Chills—Mycophenolate mofetil—systemic scleroderma	0.000481	0.00143	CcSEcCtD
Pomalidomide—Infection—Mycophenolic acid—systemic scleroderma	0.000479	0.00142	CcSEcCtD
Pomalidomide—Vertigo—Lisinopril—systemic scleroderma	0.000478	0.00142	CcSEcCtD
Pomalidomide—Diarrhoea—Mometasone—systemic scleroderma	0.000478	0.00142	CcSEcCtD
Pomalidomide—Hypokalaemia—Prednisone—systemic scleroderma	0.000478	0.00142	CcSEcCtD
Pomalidomide—Leukopenia—Lisinopril—systemic scleroderma	0.000476	0.00142	CcSEcCtD
Pomalidomide—TNF—Folate Metabolism—CCL2—systemic scleroderma	0.000476	0.00543	CbGpPWpGaD
Pomalidomide—Nervous system disorder—Mycophenolic acid—systemic scleroderma	0.000473	0.00141	CcSEcCtD
Pomalidomide—Thrombocytopenia—Mycophenolic acid—systemic scleroderma	0.000472	0.0014	CcSEcCtD
Pomalidomide—CYP1A2—Melatonin metabolism and effects—EDN1—systemic scleroderma	0.000471	0.00536	CbGpPWpGaD
Pomalidomide—Mental disorder—Mycophenolate mofetil—systemic scleroderma	0.000469	0.0014	CcSEcCtD
Pomalidomide—Skin disorder—Mycophenolic acid—systemic scleroderma	0.000468	0.00139	CcSEcCtD
Pomalidomide—Malnutrition—Mycophenolate mofetil—systemic scleroderma	0.000466	0.00139	CcSEcCtD
Pomalidomide—Hyperhidrosis—Mycophenolic acid—systemic scleroderma	0.000466	0.00139	CcSEcCtD
Pomalidomide—Cough—Lisinopril—systemic scleroderma	0.000464	0.00138	CcSEcCtD
Pomalidomide—Muscular weakness—Prednisone—systemic scleroderma	0.000463	0.00138	CcSEcCtD
Pomalidomide—Alanine aminotransferase increased—Prednisone—systemic scleroderma	0.000463	0.00138	CcSEcCtD
Pomalidomide—Gastrointestinal disorder—Azathioprine—systemic scleroderma	0.000462	0.00137	CcSEcCtD
Pomalidomide—Musculoskeletal discomfort—Leflunomide—systemic scleroderma	0.000461	0.00137	CcSEcCtD
Pomalidomide—Insomnia—Leflunomide—systemic scleroderma	0.000457	0.00136	CcSEcCtD
Pomalidomide—Arthralgia—Lisinopril—systemic scleroderma	0.000453	0.00135	CcSEcCtD
Pomalidomide—Anxiety—Lisinopril—systemic scleroderma	0.000452	0.00134	CcSEcCtD
Pomalidomide—Back pain—Mycophenolate mofetil—systemic scleroderma	0.000451	0.00134	CcSEcCtD
Pomalidomide—Dyspnoea—Leflunomide—systemic scleroderma	0.000451	0.00134	CcSEcCtD
Pomalidomide—Unspecified disorder of skin and subcutaneous tissue—Lisinopril—systemic scleroderma	0.00045	0.00134	CcSEcCtD
Pomalidomide—Muscle spasms—Mycophenolate mofetil—systemic scleroderma	0.000448	0.00133	CcSEcCtD
Pomalidomide—Vomiting—Mometasone—systemic scleroderma	0.000444	0.00132	CcSEcCtD
Pomalidomide—TNF—Vitamin B12 Metabolism—IL1B—systemic scleroderma	0.000444	0.00506	CbGpPWpGaD
Pomalidomide—Feeling abnormal—Azathioprine—systemic scleroderma	0.000441	0.00131	CcSEcCtD
Pomalidomide—Rash—Mometasone—systemic scleroderma	0.00044	0.00131	CcSEcCtD
Pomalidomide—Asthenia—Captopril—systemic scleroderma	0.00044	0.00131	CcSEcCtD
Pomalidomide—Dermatitis—Mometasone—systemic scleroderma	0.00044	0.00131	CcSEcCtD
Pomalidomide—Decreased appetite—Leflunomide—systemic scleroderma	0.000439	0.00131	CcSEcCtD
Pomalidomide—Musculoskeletal discomfort—Mycophenolic acid—systemic scleroderma	0.000439	0.00131	CcSEcCtD
Pomalidomide—Confusional state—Lisinopril—systemic scleroderma	0.000438	0.0013	CcSEcCtD
Pomalidomide—Headache—Mometasone—systemic scleroderma	0.000438	0.0013	CcSEcCtD
Pomalidomide—Tremor—Mycophenolate mofetil—systemic scleroderma	0.000437	0.0013	CcSEcCtD
Pomalidomide—Gastrointestinal disorder—Leflunomide—systemic scleroderma	0.000436	0.0013	CcSEcCtD
Pomalidomide—Insomnia—Mycophenolic acid—systemic scleroderma	0.000436	0.0013	CcSEcCtD
Pomalidomide—Fatigue—Leflunomide—systemic scleroderma	0.000436	0.0013	CcSEcCtD
Pomalidomide—TNF—Spinal Cord Injury—IL1A—systemic scleroderma	0.000435	0.00496	CbGpPWpGaD
Pomalidomide—Pruritus—Captopril—systemic scleroderma	0.000434	0.00129	CcSEcCtD
Pomalidomide—ABCB1—blood vessel—systemic scleroderma	0.000434	0.0416	CbGeAlD
Pomalidomide—Constipation—Leflunomide—systemic scleroderma	0.000432	0.00129	CcSEcCtD
Pomalidomide—Pain—Leflunomide—systemic scleroderma	0.000432	0.00129	CcSEcCtD
Pomalidomide—Infection—Lisinopril—systemic scleroderma	0.000432	0.00128	CcSEcCtD
Pomalidomide—Anaemia—Mycophenolate mofetil—systemic scleroderma	0.000431	0.00128	CcSEcCtD
Pomalidomide—Dyspnoea—Mycophenolic acid—systemic scleroderma	0.00043	0.00128	CcSEcCtD
Pomalidomide—Thrombocytopenia—Lisinopril—systemic scleroderma	0.000425	0.00126	CcSEcCtD
Pomalidomide—Neutropenia—Prednisone—systemic scleroderma	0.000424	0.00126	CcSEcCtD
Pomalidomide—Body temperature increased—Azathioprine—systemic scleroderma	0.000423	0.00126	CcSEcCtD
Pomalidomide—Skin disorder—Lisinopril—systemic scleroderma	0.000422	0.00125	CcSEcCtD
Pomalidomide—Hyperhidrosis—Lisinopril—systemic scleroderma	0.00042	0.00125	CcSEcCtD
Pomalidomide—Diarrhoea—Captopril—systemic scleroderma	0.00042	0.00125	CcSEcCtD
Pomalidomide—Decreased appetite—Mycophenolic acid—systemic scleroderma	0.000419	0.00125	CcSEcCtD
Pomalidomide—Vertigo—Mycophenolate mofetil—systemic scleroderma	0.000419	0.00125	CcSEcCtD
Pomalidomide—ABCB1—Allograft Rejection—IL13—systemic scleroderma	0.000418	0.00476	CbGpPWpGaD
Pomalidomide—Leukopenia—Mycophenolate mofetil—systemic scleroderma	0.000417	0.00124	CcSEcCtD
Pomalidomide—Feeling abnormal—Leflunomide—systemic scleroderma	0.000417	0.00124	CcSEcCtD
Pomalidomide—Gastrointestinal disorder—Mycophenolic acid—systemic scleroderma	0.000416	0.00124	CcSEcCtD
Pomalidomide—Fatigue—Mycophenolic acid—systemic scleroderma	0.000416	0.00124	CcSEcCtD
Pomalidomide—Nausea—Mometasone—systemic scleroderma	0.000415	0.00123	CcSEcCtD
Pomalidomide—Weight increased—Prednisone—systemic scleroderma	0.000413	0.00123	CcSEcCtD
Pomalidomide—Constipation—Mycophenolic acid—systemic scleroderma	0.000412	0.00123	CcSEcCtD
Pomalidomide—Pain—Mycophenolic acid—systemic scleroderma	0.000412	0.00123	CcSEcCtD
Pomalidomide—Weight decreased—Prednisone—systemic scleroderma	0.00041	0.00122	CcSEcCtD
Pomalidomide—Hyperglycaemia—Prednisone—systemic scleroderma	0.000409	0.00122	CcSEcCtD
Pomalidomide—Cough—Mycophenolate mofetil—systemic scleroderma	0.000407	0.00121	CcSEcCtD
Pomalidomide—Dizziness—Captopril—systemic scleroderma	0.000406	0.00121	CcSEcCtD
Pomalidomide—Body temperature increased—Leflunomide—systemic scleroderma	0.0004	0.00119	CcSEcCtD
Pomalidomide—Feeling abnormal—Mycophenolic acid—systemic scleroderma	0.000397	0.00118	CcSEcCtD
Pomalidomide—Arthralgia—Mycophenolate mofetil—systemic scleroderma	0.000397	0.00118	CcSEcCtD
Pomalidomide—Neuropathy peripheral—Prednisone—systemic scleroderma	0.000397	0.00118	CcSEcCtD
Pomalidomide—Breast disorder—Methotrexate—systemic scleroderma	0.000396	0.00118	CcSEcCtD
Pomalidomide—Musculoskeletal discomfort—Lisinopril—systemic scleroderma	0.000396	0.00118	CcSEcCtD
Pomalidomide—Anxiety—Mycophenolate mofetil—systemic scleroderma	0.000396	0.00118	CcSEcCtD
Pomalidomide—Hypersensitivity—Azathioprine—systemic scleroderma	0.000394	0.00117	CcSEcCtD
Pomalidomide—Unspecified disorder of skin and subcutaneous tissue—Mycophenolate mofetil—systemic scleroderma	0.000394	0.00117	CcSEcCtD
Pomalidomide—Insomnia—Lisinopril—systemic scleroderma	0.000393	0.00117	CcSEcCtD
Pomalidomide—Vomiting—Captopril—systemic scleroderma	0.00039	0.00116	CcSEcCtD
Pomalidomide—Dyspnoea—Lisinopril—systemic scleroderma	0.000387	0.00115	CcSEcCtD
Pomalidomide—Rash—Captopril—systemic scleroderma	0.000387	0.00115	CcSEcCtD
Pomalidomide—Dermatitis—Captopril—systemic scleroderma	0.000386	0.00115	CcSEcCtD
Pomalidomide—Headache—Captopril—systemic scleroderma	0.000384	0.00114	CcSEcCtD
Pomalidomide—Confusional state—Mycophenolate mofetil—systemic scleroderma	0.000384	0.00114	CcSEcCtD
Pomalidomide—Body temperature increased—Mycophenolic acid—systemic scleroderma	0.000381	0.00113	CcSEcCtD
Pomalidomide—TNF—Selenium Micronutrient Network—CCL2—systemic scleroderma	0.000378	0.00431	CbGpPWpGaD
Pomalidomide—Infection—Mycophenolate mofetil—systemic scleroderma	0.000378	0.00112	CcSEcCtD
Pomalidomide—Decreased appetite—Lisinopril—systemic scleroderma	0.000378	0.00112	CcSEcCtD
Pomalidomide—Gastrointestinal disorder—Lisinopril—systemic scleroderma	0.000375	0.00112	CcSEcCtD
Pomalidomide—TNF—Aryl Hydrocarbon Receptor Pathway—TGFB1—systemic scleroderma	0.000375	0.00427	CbGpPWpGaD
Pomalidomide—Fatigue—Lisinopril—systemic scleroderma	0.000375	0.00111	CcSEcCtD
Pomalidomide—Nervous system disorder—Mycophenolate mofetil—systemic scleroderma	0.000373	0.00111	CcSEcCtD
Pomalidomide—Thrombocytopenia—Mycophenolate mofetil—systemic scleroderma	0.000373	0.00111	CcSEcCtD
Pomalidomide—Hypersensitivity—Leflunomide—systemic scleroderma	0.000372	0.00111	CcSEcCtD
Pomalidomide—Pain—Lisinopril—systemic scleroderma	0.000371	0.0011	CcSEcCtD
Pomalidomide—Constipation—Lisinopril—systemic scleroderma	0.000371	0.0011	CcSEcCtD
Pomalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—TOP1—systemic scleroderma	0.000371	0.00422	CbGpPWpGaD
Pomalidomide—Skin disorder—Mycophenolate mofetil—systemic scleroderma	0.00037	0.0011	CcSEcCtD
Pomalidomide—Hyperhidrosis—Mycophenolate mofetil—systemic scleroderma	0.000368	0.00109	CcSEcCtD
Pomalidomide—Diarrhoea—Azathioprine—systemic scleroderma	0.000366	0.00109	CcSEcCtD
Pomalidomide—TNF—TNF alpha Signaling Pathway—CCL2—systemic scleroderma	0.000365	0.00416	CbGpPWpGaD
Pomalidomide—Nausea—Captopril—systemic scleroderma	0.000364	0.00108	CcSEcCtD
Pomalidomide—Asthenia—Leflunomide—systemic scleroderma	0.000363	0.00108	CcSEcCtD
Pomalidomide—TNF—Folate Metabolism—IL1B—systemic scleroderma	0.000361	0.00412	CbGpPWpGaD
Pomalidomide—Pancytopenia—Methotrexate—systemic scleroderma	0.00036	0.00107	CcSEcCtD
Pomalidomide—PTGS2—connective tissue—systemic scleroderma	0.00036	0.0344	CbGeAlD
Pomalidomide—Feeling abnormal—Lisinopril—systemic scleroderma	0.000358	0.00106	CcSEcCtD
Pomalidomide—Pruritus—Leflunomide—systemic scleroderma	0.000358	0.00106	CcSEcCtD
Pomalidomide—Connective tissue disorder—Prednisone—systemic scleroderma	0.000357	0.00106	CcSEcCtD
Pomalidomide—Neutropenia—Methotrexate—systemic scleroderma	0.000355	0.00105	CcSEcCtD
Pomalidomide—Dizziness—Azathioprine—systemic scleroderma	0.000354	0.00105	CcSEcCtD
Pomalidomide—Upper respiratory tract infection—Methotrexate—systemic scleroderma	0.000352	0.00105	CcSEcCtD
Pomalidomide—TNF—SIDS Susceptibility Pathways—IL1A—systemic scleroderma	0.000348	0.00397	CbGpPWpGaD
Pomalidomide—Musculoskeletal discomfort—Mycophenolate mofetil—systemic scleroderma	0.000347	0.00103	CcSEcCtD
Pomalidomide—Asthenia—Mycophenolic acid—systemic scleroderma	0.000346	0.00103	CcSEcCtD
Pomalidomide—Diarrhoea—Leflunomide—systemic scleroderma	0.000346	0.00103	CcSEcCtD
Pomalidomide—Insomnia—Mycophenolate mofetil—systemic scleroderma	0.000344	0.00102	CcSEcCtD
Pomalidomide—Body temperature increased—Lisinopril—systemic scleroderma	0.000343	0.00102	CcSEcCtD
Pomalidomide—Pruritus—Mycophenolic acid—systemic scleroderma	0.000341	0.00101	CcSEcCtD
Pomalidomide—Vomiting—Azathioprine—systemic scleroderma	0.00034	0.00101	CcSEcCtD
Pomalidomide—Pneumonia—Methotrexate—systemic scleroderma	0.00034	0.00101	CcSEcCtD
Pomalidomide—Dyspnoea—Mycophenolate mofetil—systemic scleroderma	0.000339	0.00101	CcSEcCtD
Pomalidomide—Infestation—Methotrexate—systemic scleroderma	0.000338	0.00101	CcSEcCtD
Pomalidomide—Infestation NOS—Methotrexate—systemic scleroderma	0.000338	0.00101	CcSEcCtD
Pomalidomide—Rash—Azathioprine—systemic scleroderma	0.000338	0.001	CcSEcCtD
Pomalidomide—Dermatitis—Azathioprine—systemic scleroderma	0.000337	0.001	CcSEcCtD
Pomalidomide—ABCB1—Allograft Rejection—CTLA4—systemic scleroderma	0.000336	0.00383	CbGpPWpGaD
Pomalidomide—Headache—Azathioprine—systemic scleroderma	0.000335	0.000997	CcSEcCtD
Pomalidomide—Dizziness—Leflunomide—systemic scleroderma	0.000334	0.000994	CcSEcCtD
Pomalidomide—Renal failure—Methotrexate—systemic scleroderma	0.000332	0.000988	CcSEcCtD
Pomalidomide—Decreased appetite—Mycophenolate mofetil—systemic scleroderma	0.000331	0.000984	CcSEcCtD
Pomalidomide—Diarrhoea—Mycophenolic acid—systemic scleroderma	0.00033	0.000981	CcSEcCtD
Pomalidomide—TNF—TGF-beta Receptor Signaling—TGFB1—systemic scleroderma	0.00033	0.00375	CbGpPWpGaD
Pomalidomide—Angiopathy—Prednisone—systemic scleroderma	0.000329	0.00098	CcSEcCtD
Pomalidomide—PTGS2—smooth muscle tissue—systemic scleroderma	0.000329	0.0315	CbGeAlD
Pomalidomide—Gastrointestinal disorder—Mycophenolate mofetil—systemic scleroderma	0.000329	0.000977	CcSEcCtD
Pomalidomide—TNF—MAPK Signaling Pathway—IL1A—systemic scleroderma	0.000328	0.00374	CbGpPWpGaD
Pomalidomide—Pain—Mycophenolate mofetil—systemic scleroderma	0.000325	0.000968	CcSEcCtD
Pomalidomide—Constipation—Mycophenolate mofetil—systemic scleroderma	0.000325	0.000968	CcSEcCtD
Pomalidomide—PTGS2—skin of body—systemic scleroderma	0.000325	0.0311	CbGeAlD
Pomalidomide—TNF—Cardiac Hypertrophic Response—TGFB1—systemic scleroderma	0.000325	0.0037	CbGpPWpGaD
Pomalidomide—Vomiting—Leflunomide—systemic scleroderma	0.000321	0.000956	CcSEcCtD
Pomalidomide—Hypersensitivity—Lisinopril—systemic scleroderma	0.00032	0.000952	CcSEcCtD
Pomalidomide—Hepatobiliary disease—Methotrexate—systemic scleroderma	0.00032	0.000951	CcSEcCtD
Pomalidomide—Dizziness—Mycophenolic acid—systemic scleroderma	0.000319	0.000949	CcSEcCtD
Pomalidomide—Epistaxis—Methotrexate—systemic scleroderma	0.000319	0.000948	CcSEcCtD
Pomalidomide—Rash—Leflunomide—systemic scleroderma	0.000319	0.000948	CcSEcCtD
Pomalidomide—Dermatitis—Leflunomide—systemic scleroderma	0.000318	0.000947	CcSEcCtD
Pomalidomide—Mental disorder—Prednisone—systemic scleroderma	0.000318	0.000946	CcSEcCtD
Pomalidomide—Nausea—Azathioprine—systemic scleroderma	0.000318	0.000946	CcSEcCtD
Pomalidomide—Headache—Leflunomide—systemic scleroderma	0.000317	0.000942	CcSEcCtD
Pomalidomide—Malnutrition—Prednisone—systemic scleroderma	0.000316	0.00094	CcSEcCtD
Pomalidomide—Feeling abnormal—Mycophenolate mofetil—systemic scleroderma	0.000314	0.000933	CcSEcCtD
Pomalidomide—CYP1A2—digestive system—systemic scleroderma	0.000314	0.03	CbGeAlD
Pomalidomide—TNF—Allograft Rejection—IL1B—systemic scleroderma	0.000313	0.00356	CbGpPWpGaD
Pomalidomide—TNF—Alzheimers Disease—IL1B—systemic scleroderma	0.000313	0.00356	CbGpPWpGaD
Pomalidomide—Asthenia—Lisinopril—systemic scleroderma	0.000312	0.000927	CcSEcCtD
Pomalidomide—Pruritus—Lisinopril—systemic scleroderma	0.000307	0.000914	CcSEcCtD
Pomalidomide—Vomiting—Mycophenolic acid—systemic scleroderma	0.000307	0.000912	CcSEcCtD
Pomalidomide—ABCB1—HIF-1-alpha transcription factor network—EDN1—systemic scleroderma	0.000305	0.00348	CbGpPWpGaD
Pomalidomide—Rash—Mycophenolic acid—systemic scleroderma	0.000304	0.000904	CcSEcCtD
Pomalidomide—Dermatitis—Mycophenolic acid—systemic scleroderma	0.000304	0.000904	CcSEcCtD
Pomalidomide—Headache—Mycophenolic acid—systemic scleroderma	0.000302	0.000899	CcSEcCtD
Pomalidomide—Body temperature increased—Mycophenolate mofetil—systemic scleroderma	0.000301	0.000895	CcSEcCtD
Pomalidomide—Nausea—Leflunomide—systemic scleroderma	0.0003	0.000893	CcSEcCtD
Pomalidomide—Urinary tract disorder—Methotrexate—systemic scleroderma	0.0003	0.000891	CcSEcCtD
Pomalidomide—TNF—Spinal Cord Injury—CCL2—systemic scleroderma	0.000299	0.00341	CbGpPWpGaD
Pomalidomide—Urethral disorder—Methotrexate—systemic scleroderma	0.000298	0.000885	CcSEcCtD
Pomalidomide—Diarrhoea—Lisinopril—systemic scleroderma	0.000297	0.000884	CcSEcCtD
Pomalidomide—Anaemia—Prednisone—systemic scleroderma	0.000292	0.000869	CcSEcCtD
Pomalidomide—Dizziness—Lisinopril—systemic scleroderma	0.000287	0.000854	CcSEcCtD
Pomalidomide—TNF—Selenium Micronutrient Network—IL1B—systemic scleroderma	0.000287	0.00327	CbGpPWpGaD
Pomalidomide—Nausea—Mycophenolic acid—systemic scleroderma	0.000286	0.000852	CcSEcCtD
Pomalidomide—Vertigo—Prednisone—systemic scleroderma	0.000284	0.000845	CcSEcCtD
Pomalidomide—Cardiac disorder—Methotrexate—systemic scleroderma	0.000282	0.000838	CcSEcCtD
Pomalidomide—Hypersensitivity—Mycophenolate mofetil—systemic scleroderma	0.00028	0.000834	CcSEcCtD
Pomalidomide—ABCB1—Allograft Rejection—HLA-DQB1—systemic scleroderma	0.000277	0.00315	CbGpPWpGaD
Pomalidomide—Vomiting—Lisinopril—systemic scleroderma	0.000276	0.000821	CcSEcCtD
Pomalidomide—Angiopathy—Methotrexate—systemic scleroderma	0.000275	0.000819	CcSEcCtD
Pomalidomide—Rash—Lisinopril—systemic scleroderma	0.000274	0.000815	CcSEcCtD
Pomalidomide—Dermatitis—Lisinopril—systemic scleroderma	0.000274	0.000814	CcSEcCtD
Pomalidomide—Mediastinal disorder—Methotrexate—systemic scleroderma	0.000274	0.000813	CcSEcCtD
Pomalidomide—Asthenia—Mycophenolate mofetil—systemic scleroderma	0.000273	0.000812	CcSEcCtD
Pomalidomide—TNF—Developmental Biology—RHOB—systemic scleroderma	0.000273	0.00311	CbGpPWpGaD
Pomalidomide—Chills—Methotrexate—systemic scleroderma	0.000272	0.00081	CcSEcCtD
Pomalidomide—Headache—Lisinopril—systemic scleroderma	0.000272	0.000809	CcSEcCtD
Pomalidomide—Pruritus—Mycophenolate mofetil—systemic scleroderma	0.000269	0.000801	CcSEcCtD
Pomalidomide—Arthralgia—Prednisone—systemic scleroderma	0.000269	0.0008	CcSEcCtD
Pomalidomide—PTGS2—Spinal Cord Injury—IL1A—systemic scleroderma	0.000269	0.00307	CbGpPWpGaD
Pomalidomide—Anxiety—Prednisone—systemic scleroderma	0.000268	0.000798	CcSEcCtD
Pomalidomide—Unspecified disorder of skin and subcutaneous tissue—Prednisone—systemic scleroderma	0.000267	0.000795	CcSEcCtD
Pomalidomide—Mental disorder—Methotrexate—systemic scleroderma	0.000266	0.000791	CcSEcCtD
Pomalidomide—Malnutrition—Methotrexate—systemic scleroderma	0.000264	0.000786	CcSEcCtD
Pomalidomide—ABCB1—Allograft Rejection—IL1A—systemic scleroderma	0.000263	0.003	CbGpPWpGaD
Pomalidomide—CYP1A2—lung—systemic scleroderma	0.000262	0.0251	CbGeAlD
Pomalidomide—ABCB1—Allograft Rejection—CD40LG—systemic scleroderma	0.000261	0.00298	CbGpPWpGaD
Pomalidomide—Diarrhoea—Mycophenolate mofetil—systemic scleroderma	0.00026	0.000775	CcSEcCtD
Pomalidomide—PTGS2—digestive system—systemic scleroderma	0.00026	0.0249	CbGeAlD
Pomalidomide—Nausea—Lisinopril—systemic scleroderma	0.000258	0.000767	CcSEcCtD
Pomalidomide—Infection—Prednisone—systemic scleroderma	0.000256	0.000762	CcSEcCtD
Pomalidomide—Back pain—Methotrexate—systemic scleroderma	0.000256	0.00076	CcSEcCtD
Pomalidomide—TNF—Toll-like Receptor Signaling Pathway—IL1B—systemic scleroderma	0.000255	0.0029	CbGpPWpGaD
Pomalidomide—Nervous system disorder—Prednisone—systemic scleroderma	0.000253	0.000752	CcSEcCtD
Pomalidomide—Dizziness—Mycophenolate mofetil—systemic scleroderma	0.000252	0.000749	CcSEcCtD
Pomalidomide—Skin disorder—Prednisone—systemic scleroderma	0.000251	0.000745	CcSEcCtD
Pomalidomide—Hyperhidrosis—Prednisone—systemic scleroderma	0.000249	0.000742	CcSEcCtD
Pomalidomide—TNF—Transcriptional regulation of white adipocyte differentiation—TGFB1—systemic scleroderma	0.000248	0.00283	CbGpPWpGaD
Pomalidomide—PTGS2—tendon—systemic scleroderma	0.000247	0.0237	CbGeAlD
Pomalidomide—Anaemia—Methotrexate—systemic scleroderma	0.000244	0.000726	CcSEcCtD
Pomalidomide—TNF—Allograft Rejection—TGFB1—systemic scleroderma	0.000243	0.00277	CbGpPWpGaD
Pomalidomide—Vomiting—Mycophenolate mofetil—systemic scleroderma	0.000242	0.00072	CcSEcCtD
Pomalidomide—Rash—Mycophenolate mofetil—systemic scleroderma	0.00024	0.000714	CcSEcCtD
Pomalidomide—Dermatitis—Mycophenolate mofetil—systemic scleroderma	0.00024	0.000713	CcSEcCtD
Pomalidomide—Headache—Mycophenolate mofetil—systemic scleroderma	0.000238	0.000709	CcSEcCtD
Pomalidomide—Vertigo—Methotrexate—systemic scleroderma	0.000237	0.000706	CcSEcCtD
Pomalidomide—Leukopenia—Methotrexate—systemic scleroderma	0.000236	0.000703	CcSEcCtD
Pomalidomide—Musculoskeletal discomfort—Prednisone—systemic scleroderma	0.000235	0.000699	CcSEcCtD
Pomalidomide—PTGS2—Selenium Micronutrient Network—CCL2—systemic scleroderma	0.000234	0.00267	CbGpPWpGaD
Pomalidomide—Insomnia—Prednisone—systemic scleroderma	0.000233	0.000694	CcSEcCtD
Pomalidomide—TNF—MicroRNAs in cardiomyocyte hypertrophy—TGFB1—systemic scleroderma	0.000231	0.00264	CbGpPWpGaD
Pomalidomide—Cough—Methotrexate—systemic scleroderma	0.000231	0.000686	CcSEcCtD
Pomalidomide—CYP3A4—digestive system—systemic scleroderma	0.000227	0.0217	CbGeAlD
Pomalidomide—TNF—Spinal Cord Injury—IL1B—systemic scleroderma	0.000227	0.00259	CbGpPWpGaD
Pomalidomide—Nausea—Mycophenolate mofetil—systemic scleroderma	0.000226	0.000672	CcSEcCtD
Pomalidomide—Arthralgia—Methotrexate—systemic scleroderma	0.000225	0.000669	CcSEcCtD
Pomalidomide—Decreased appetite—Prednisone—systemic scleroderma	0.000224	0.000667	CcSEcCtD
Pomalidomide—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—systemic scleroderma	0.000223	0.000664	CcSEcCtD
Pomalidomide—Fatigue—Prednisone—systemic scleroderma	0.000222	0.000662	CcSEcCtD
Pomalidomide—Constipation—Prednisone—systemic scleroderma	0.000221	0.000656	CcSEcCtD
Pomalidomide—Confusional state—Methotrexate—systemic scleroderma	0.000217	0.000647	CcSEcCtD
Pomalidomide—PTGS2—lung—systemic scleroderma	0.000217	0.0208	CbGeAlD
Pomalidomide—Infection—Methotrexate—systemic scleroderma	0.000214	0.000637	CcSEcCtD
Pomalidomide—TNF—Spinal Cord Injury—MMP9—systemic scleroderma	0.000214	0.00244	CbGpPWpGaD
Pomalidomide—Feeling abnormal—Prednisone—systemic scleroderma	0.000213	0.000632	CcSEcCtD
Pomalidomide—Nervous system disorder—Methotrexate—systemic scleroderma	0.000211	0.000629	CcSEcCtD
Pomalidomide—Thrombocytopenia—Methotrexate—systemic scleroderma	0.000211	0.000628	CcSEcCtD
Pomalidomide—Skin disorder—Methotrexate—systemic scleroderma	0.000209	0.000623	CcSEcCtD
Pomalidomide—Hyperhidrosis—Methotrexate—systemic scleroderma	0.000208	0.00062	CcSEcCtD
Pomalidomide—Body temperature increased—Prednisone—systemic scleroderma	0.000204	0.000607	CcSEcCtD
Pomalidomide—TNF—Regulation of toll-like receptor signaling pathway—IL1B—systemic scleroderma	0.000199	0.00227	CbGpPWpGaD
Pomalidomide—Musculoskeletal discomfort—Methotrexate—systemic scleroderma	0.000196	0.000584	CcSEcCtD
Pomalidomide—Insomnia—Methotrexate—systemic scleroderma	0.000195	0.00058	CcSEcCtD
Pomalidomide—Dyspnoea—Methotrexate—systemic scleroderma	0.000192	0.000572	CcSEcCtD
Pomalidomide—Hypersensitivity—Prednisone—systemic scleroderma	0.00019	0.000565	CcSEcCtD
Pomalidomide—Decreased appetite—Methotrexate—systemic scleroderma	0.000187	0.000557	CcSEcCtD
Pomalidomide—Gastrointestinal disorder—Methotrexate—systemic scleroderma	0.000186	0.000554	CcSEcCtD
Pomalidomide—Fatigue—Methotrexate—systemic scleroderma	0.000186	0.000553	CcSEcCtD
Pomalidomide—Asthenia—Prednisone—systemic scleroderma	0.000185	0.000551	CcSEcCtD
Pomalidomide—PTGS2—Spinal Cord Injury—CCL2—systemic scleroderma	0.000185	0.00211	CbGpPWpGaD
Pomalidomide—Pain—Methotrexate—systemic scleroderma	0.000184	0.000548	CcSEcCtD
Pomalidomide—Pruritus—Prednisone—systemic scleroderma	0.000183	0.000543	CcSEcCtD
Pomalidomide—TNF—SIDS Susceptibility Pathways—IL1B—systemic scleroderma	0.000181	0.00207	CbGpPWpGaD
Pomalidomide—Feeling abnormal—Methotrexate—systemic scleroderma	0.000178	0.000528	CcSEcCtD
Pomalidomide—PTGS2—Selenium Micronutrient Network—IL1B—systemic scleroderma	0.000177	0.00202	CbGpPWpGaD
Pomalidomide—Diarrhoea—Prednisone—systemic scleroderma	0.000177	0.000525	CcSEcCtD
Pomalidomide—TNF—Spinal Cord Injury—TGFB1—systemic scleroderma	0.000176	0.00201	CbGpPWpGaD
Pomalidomide—TNF—MAPK Signaling Pathway—IL1B—systemic scleroderma	0.000171	0.00195	CbGpPWpGaD
Pomalidomide—Dizziness—Prednisone—systemic scleroderma	0.000171	0.000507	CcSEcCtD
Pomalidomide—Body temperature increased—Methotrexate—systemic scleroderma	0.00017	0.000507	CcSEcCtD
Pomalidomide—CYP1A2—Aryl Hydrocarbon Receptor Pathway—IL1B—systemic scleroderma	0.000169	0.00192	CbGpPWpGaD
Pomalidomide—Vomiting—Prednisone—systemic scleroderma	0.000164	0.000488	CcSEcCtD
Pomalidomide—TNF—Adipogenesis—TGFB1—systemic scleroderma	0.000163	0.00186	CbGpPWpGaD
Pomalidomide—Rash—Prednisone—systemic scleroderma	0.000163	0.000484	CcSEcCtD
Pomalidomide—Dermatitis—Prednisone—systemic scleroderma	0.000163	0.000483	CcSEcCtD
Pomalidomide—Headache—Prednisone—systemic scleroderma	0.000162	0.000481	CcSEcCtD
Pomalidomide—ABCB1—digestive system—systemic scleroderma	0.000161	0.0154	CbGeAlD
Pomalidomide—Hypersensitivity—Methotrexate—systemic scleroderma	0.000159	0.000472	CcSEcCtD
Pomalidomide—Asthenia—Methotrexate—systemic scleroderma	0.000155	0.00046	CcSEcCtD
Pomalidomide—Nausea—Prednisone—systemic scleroderma	0.000153	0.000456	CcSEcCtD
Pomalidomide—Pruritus—Methotrexate—systemic scleroderma	0.000153	0.000454	CcSEcCtD
Pomalidomide—Diarrhoea—Methotrexate—systemic scleroderma	0.000148	0.000439	CcSEcCtD
Pomalidomide—Dizziness—Methotrexate—systemic scleroderma	0.000143	0.000424	CcSEcCtD
Pomalidomide—PTGS2—Metabolism of lipids and lipoproteins—HSPG2—systemic scleroderma	0.000142	0.00162	CbGpPWpGaD
Pomalidomide—PTGS2—Spinal Cord Injury—IL1B—systemic scleroderma	0.00014	0.0016	CbGpPWpGaD
Pomalidomide—ABCB1—Allograft Rejection—IL1B—systemic scleroderma	0.000137	0.00156	CbGpPWpGaD
Pomalidomide—Vomiting—Methotrexate—systemic scleroderma	0.000137	0.000408	CcSEcCtD
Pomalidomide—Rash—Methotrexate—systemic scleroderma	0.000136	0.000404	CcSEcCtD
Pomalidomide—Dermatitis—Methotrexate—systemic scleroderma	0.000136	0.000404	CcSEcCtD
Pomalidomide—Headache—Methotrexate—systemic scleroderma	0.000135	0.000402	CcSEcCtD
Pomalidomide—ABCB1—lung—systemic scleroderma	0.000134	0.0129	CbGeAlD
Pomalidomide—TNF—MAPK Signaling Pathway—TGFB1—systemic scleroderma	0.000133	0.00151	CbGpPWpGaD
Pomalidomide—PTGS2—Spinal Cord Injury—MMP9—systemic scleroderma	0.000132	0.00151	CbGpPWpGaD
Pomalidomide—CYP1A2—Aryl Hydrocarbon Receptor Pathway—TGFB1—systemic scleroderma	0.000131	0.00149	CbGpPWpGaD
Pomalidomide—Nausea—Methotrexate—systemic scleroderma	0.000128	0.000381	CcSEcCtD
Pomalidomide—TNF—Integrated Pancreatic Cancer Pathway—TGFB1—systemic scleroderma	0.00012	0.00137	CbGpPWpGaD
Pomalidomide—PTGS2—Spinal Cord Injury—TGFB1—systemic scleroderma	0.000109	0.00124	CbGpPWpGaD
Pomalidomide—PTGS2—Metabolism of lipids and lipoproteins—CTGF—systemic scleroderma	0.000108	0.00123	CbGpPWpGaD
Pomalidomide—ABCB1—Allograft Rejection—TGFB1—systemic scleroderma	0.000107	0.00121	CbGpPWpGaD
Pomalidomide—PTGS2—Disease—SMAD7—systemic scleroderma	0.000104	0.00118	CbGpPWpGaD
Pomalidomide—PTGS2—Disease—TGFBI—systemic scleroderma	9.47e-05	0.00108	CbGpPWpGaD
Pomalidomide—TNF—Developmental Biology—MMP2—systemic scleroderma	9.05e-05	0.00103	CbGpPWpGaD
Pomalidomide—CYP1A2—Metabolism of lipids and lipoproteins—HSPG2—systemic scleroderma	8.04e-05	0.000916	CbGpPWpGaD
Pomalidomide—PTGS2—Disease—HSPG2—systemic scleroderma	7.55e-05	0.00086	CbGpPWpGaD
Pomalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—TGFB1—systemic scleroderma	7.42e-05	0.000845	CbGpPWpGaD
Pomalidomide—PTGS2—Disease—CSK—systemic scleroderma	7.29e-05	0.000831	CbGpPWpGaD
Pomalidomide—PTGS2—Disease—CD247—systemic scleroderma	6.86e-05	0.000781	CbGpPWpGaD
Pomalidomide—TNF—Developmental Biology—MMP9—systemic scleroderma	6.8e-05	0.000775	CbGpPWpGaD
Pomalidomide—PTGS2—Metabolism—HSPG2—systemic scleroderma	6.32e-05	0.000721	CbGpPWpGaD
Pomalidomide—CYP1A2—Metabolism of lipids and lipoproteins—CTGF—systemic scleroderma	6.09e-05	0.000694	CbGpPWpGaD
Pomalidomide—TNF—Developmental Biology—TGFB1—systemic scleroderma	5.61e-05	0.000639	CbGpPWpGaD
Pomalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—TGFB1—systemic scleroderma	5.26e-05	0.000599	CbGpPWpGaD
Pomalidomide—PTGS2—Metabolism—CTGF—systemic scleroderma	4.79e-05	0.000546	CbGpPWpGaD
Pomalidomide—ABCB1—Metabolism—HSPG2—systemic scleroderma	4.48e-05	0.000511	CbGpPWpGaD
Pomalidomide—CYP1A2—Metabolism—HSPG2—systemic scleroderma	3.58e-05	0.000408	CbGpPWpGaD
Pomalidomide—ABCB1—Metabolism—CTGF—systemic scleroderma	3.4e-05	0.000387	CbGpPWpGaD
Pomalidomide—CYP3A4—Metabolism—HSPG2—systemic scleroderma	2.76e-05	0.000315	CbGpPWpGaD
Pomalidomide—CYP1A2—Metabolism—CTGF—systemic scleroderma	2.71e-05	0.000309	CbGpPWpGaD
Pomalidomide—PTGS2—Disease—NOS3—systemic scleroderma	2.49e-05	0.000284	CbGpPWpGaD
Pomalidomide—CYP3A4—Metabolism—CTGF—systemic scleroderma	2.09e-05	0.000239	CbGpPWpGaD
Pomalidomide—PTGS2—Metabolism—NOS3—systemic scleroderma	2.09e-05	0.000238	CbGpPWpGaD
Pomalidomide—PTGS2—Disease—TGFB1—systemic scleroderma	1.65e-05	0.000188	CbGpPWpGaD
Pomalidomide—ABCB1—Metabolism—NOS3—systemic scleroderma	1.48e-05	0.000169	CbGpPWpGaD
Pomalidomide—CYP1A2—Metabolism—NOS3—systemic scleroderma	1.18e-05	0.000135	CbGpPWpGaD
Pomalidomide—CYP3A4—Metabolism—NOS3—systemic scleroderma	9.11e-06	0.000104	CbGpPWpGaD
